Pulse Biosciences 향후 성장

Future 기준 점검 2/6

Pulse Biosciences은 연간 수입과 매출이 각각 19.5%와 57.3% 증가할 것으로 예상되고 EPS는 연간 20.6%만큼 증가할 것으로 예상됩니다.

핵심 정보

19.5%

이익 성장률

20.56%

EPS 성장률

Medical Equipment 이익 성장	15.9%
매출 성장률	57.3%
향후 자기자본이익률	n/a
애널리스트 커버리지	Low
마지막 업데이트	17 Mar 2026

최근 향후 성장 업데이트

Recent updates

Early Thyroid And Cardiac Applications Will Establish A Powerful Medical Device Platform

Feb 09Catalysts About Pulse Biosciences Pulse Biosciences develops and commercializes medical devices that use proprietary nanosecond pulse field ablation technology for soft tissue and cardiac applications. What are the underlying business or industry changes driving this perspective?

Pulse Biosciences (NASDAQ:PLSE) Is In A Good Position To Deliver On Growth Plans

Dec 21

Here's Why We're Not At All Concerned With Pulse Biosciences' (NASDAQ:PLSE) Cash Burn Situation

Jun 12

이익 및 매출 성장 예측

NasdaqCM:PLSE - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2028	41	-81	-77	N/A	1
12/31/2027	13	-100	-75	N/A	2
12/31/2026	3	-92	-68	N/A	2
12/31/2025	0	-73	-54	-54	N/A
9/30/2025	0	-75	-49	-49	N/A
6/30/2025	N/A	-68	-45	-44	N/A
3/31/2025	N/A	-60	-40	-40	N/A
12/31/2024	N/A	-54	-36	-36	N/A
9/30/2024	N/A	-46	-34	-34	N/A
6/30/2024	N/A	-44	-36	-35	N/A
3/31/2024	N/A	-43	-36	-36	N/A
12/31/2023	N/A	-42	-33	-33	N/A
9/30/2023	0	-39	-34	-34	N/A
6/30/2023	0	-47	-35	-34	N/A
3/31/2023	0	-51	-38	-38	N/A
12/31/2022	1	-59	-47	-47	N/A
9/30/2022	2	-65	-52	-52	N/A
6/30/2022	2	-61	-55	-54	N/A
3/31/2022	2	-62	-59	-58	N/A
12/31/2021	1	-64	-55	-54	N/A
9/30/2021	1	-62	-51	-51	N/A
6/30/2021	N/A	-61	-46	-46	N/A
3/31/2021	N/A	-57	-38	-37	N/A
12/31/2020	N/A	-50	-36	-35	N/A
9/30/2020	N/A	-50	-35	-35	N/A
6/30/2020	N/A	-49	-35	-35	N/A
3/31/2020	N/A	-49	-37	-36	N/A
12/31/2019	N/A	-47	-35	-34	N/A
9/30/2019	N/A	-42	N/A	-31	N/A
6/30/2019	N/A	-41	N/A	-30	N/A
3/31/2019	N/A	-39	N/A	-26	N/A
12/31/2018	N/A	-38	N/A	-24	N/A
9/30/2018	N/A	-37	N/A	-22	N/A
6/30/2018	N/A	-34	N/A	-18	N/A
3/31/2018	N/A	-31	N/A	-14	N/A
12/31/2017	N/A	-26	N/A	-11	N/A
9/30/2017	N/A	-20	N/A	-9	N/A
6/30/2017	N/A	-15	N/A	-8	N/A
3/31/2017	N/A	-11	N/A	-9	N/A
12/31/2016	N/A	-10	N/A	-8	N/A
9/30/2016	N/A	-8	N/A	-7	N/A
6/30/2016	N/A	-6	N/A	-6	N/A
3/31/2016	N/A	-4	N/A	-4	N/A
12/31/2015	N/A	-3	N/A	-3	N/A

애널리스트 향후 성장 전망

수입 대 저축률: PLSE 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: PLSE 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: PLSE 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: PLSE 의 수익(연간 57.3%)이 US 시장(연간 10.4%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 매출: PLSE 의 수익(연간 57.3%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: PLSE의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/03/22 20:09
종가	2026/03/20 00:00
수익	2025/12/31
연간 수익	2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 우리의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Pulse Biosciences, Inc.는 3명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Anthony Petrone	Mizuho Securities USA LLC
Suraj Kalia	Oppenheimer & Co. Inc.
Christopher Cooley	Stephens, Inc.

Pulse Biosciences 향후 성장

Future 기준 점검 2/6

핵심 정보

최근 향후 성장 업데이트

No longer forecast to breakeven

No longer forecast to breakeven

Consensus revenue estimates fall by 31%

Consensus forecasts updated

Price target decreased to US$11.17

Consensus forecasts updated

Recent updates

Pulse Biosciences Announces Strategic Alignment to Accelerate Cardiac Catheter Program

Pulse Biosciences, Inc. Announces First Enrollments in Feasibility Study for the Treatment of Malignant Thyroid Tumors with Npulse Vybrance Percutaneous Electrode System

Pulse Biosciences Announces Clinical Data From nPulse Vybrance System First-In-Human Clinical Durability Study Of Benign Thyroid Nodule Ablation

No longer forecast to breakeven

Pulse Biosciences, Inc. has withdrawn its Follow-on Equity Offering in the amount of $60 million.

Chief Commercial Officer notifies of intention to sell stock

Early Thyroid And Cardiac Applications Will Establish A Powerful Medical Device Platform

New major risk - Share price stability

Pulse Biosciences, Inc. Presents Late-Breaking Data from nPulse™? Cardiac Catheter System First-In-Human Feasibility Study at the AF Symposium

Pulse Biosciences, Inc. to Report Q4, 2025 Results on Feb 19, 2026

No longer forecast to breakeven

Pulse Biosciences, Inc. Appoints Maria Sainz to Its Board of Directors, Effective January 9, 2026

Pulse Biosciences Selects to Present Late-Breaking Data from the nPulse Cardiac Catheter Study at the AF Symposium

Pulse Biosciences (NASDAQ:PLSE) Is In A Good Position To Deliver On Growth Plans

Pulse Biosciences, Inc. Announces FDA Ide Approval to Initiate Its nPulse Cardiac Catheter Ablation System Study for the Treatment of Atrial Fibrillation

Pulse Biosciences, Inc., Annual General Meeting, Dec 09, 2025

Pulse Biosciences, Inc. Announces First Enrollment in the NANOCLAMP AF Study

Pulse Biosciences, Inc. to Report Q3, 2025 Results on Nov 05, 2025

Pulse Biosciences, Inc. Announces Presentation of Late-Breaking Data from the nPulse Cardiac Surgical System First-In-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting

CTO & Director exercised options and sold US$822k worth of stock

Independent Co-Chairman recently bought US$2.6m worth of stock

Pulse Biosciences Announces Fda Ide Approval to Initiate Its Nspfa Cardiac Surgery System Study for the Treatment of Atrial Fibrillation

Pulse Biosciences, Inc. Announces First Successful Procedures in PRECISE Benign Thyroid Nodule (BTN) Study

Pulse Biosciences, Inc. Announces Publication of First-In-Human Data for Treatment of Benign Thyroid Nodules in the Journal Thyroid

Pulse Biosciences, Inc. to Report Q2, 2025 Results on Aug 12, 2025

New major risk - Revenue and earnings growth

CTO & Director recently sold US$486k worth of stock

Here's Why We're Not At All Concerned With Pulse Biosciences' (NASDAQ:PLSE) Cash Burn Situation

Pulse Biosciences, Inc. to Report Q1, 2025 Results on May 08, 2025

Pulse Biosciences, Inc. to Report Q4, 2024 Results on Mar 27, 2025

Independent Director exercised options to buy US$1.3m worth of stock.

We're Not Very Worried About Pulse Biosciences' (NASDAQ:PLSE) Cash Burn Rate

Pulse Biosciences, Inc. Announces the Appointment of Jon Skinner as Chief Financial Officer

Pulse Biosciences Announces Late-Breaking Data from its Nanosecond PFA 360° Cardiac Catheter System First-In-Human Feasibility Study Presented at the AF Symposium

Pulse Biosciences, Inc. Appoints Paul A. LaViolette as Chief Executive Officer

Executive Co-Chairman exercised options to buy US$94m worth of stock.

Executive Co-Chairman recently bought US$972k worth of stock

Pulse Biosciences, Inc. Announces Positive Clinical Data Presented At the American Thyroid Association

Pulse Biosciences, Inc. Announces Appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology

Pulse Biosciences, Inc. to Report Q3, 2024 Results on Oct 30, 2024

Pulse Biosciences, Inc. announced delayed 10-Q filing

Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors

Pulse Biosciences, Inc. Announces Successful Treatment of Patients in First-in-Human Study with its Nano-PFA Cardiac Surgery System

Pulse Biosciences, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Pulse Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $60 million.

Pulse Biosciences, Inc. Announces Receipt of FDA Breakthrough Device Designation for CellFX® nsPFA Cardiac Surgery System for the Treatment of Atrial Fibrillation

Pulse Biosciences, Inc.(NasdaqCM:PLSE) dropped from Russell Small Cap Comp Value Index

Shelley D. Spray Does Not Stand for Reelection from the Board of Pulse Biosciences, Inc

President & CEO recently bought US$86k worth of stock

Pulse Biosciences Stock: Signs Of Life Following Q1 Update

Pulse Biosciences, Inc Announces CEO Changes

We're Keeping An Eye On Pulse Biosciences' (NASDAQ:PLSE) Cash Burn Rate

Pulse Biosciences, Inc. Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System

New major risk - Financial position

Pulse Biosciences, Inc. to Report Q1, 2024 Results on May 07, 2024

Pulse Biosciences, Inc., Annual General Meeting, Jun 06, 2024

Pulse Biosciences, Inc. to Report Q4, 2023 Results on Mar 28, 2024

Pulse Biosciences, Inc. Announces FDA 510(K) Clearance for its CellFX nsPFA Percutaneous Electrode System

Pulse Biosciences Files 510(K) Submission with U.S. FDA for its CellFX nsPFA Cardiac Clamp

We Think Pulse Biosciences (NASDAQ:PLSE) Can Afford To Drive Business Growth

Pulse Biosciences, Inc. Announces First-In-Human Procedures with its Novel CellFX Nanosecond Pulsed Field Ablation Cardiac Catheter

Executive Chairman exercised options to buy US$382k worth of stock.

Executive Chairman recently bought US$1.1m worth of stock

Pulse Biosciences, Inc. Announces Filing of Premarket Notification 510(k) to U.S. Food and Drug Administration for its Novel CellFX nsPFA Percutaneous Electrode

Chief Strategy Officer recently bought US$105k worth of stock

Executive Chairman exercised options to buy US$68k worth of stock.

Pulse Biosciences, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Pulse Biosciences, Inc. Appoints Dr. Niv Ad as Chief Science Officer, Cardiac Surgery

We Think Pulse Biosciences (NASDAQ:PLSE) Can Afford To Drive Business Growth